University of Tennessee, Knoxville

TRACE: Tennessee Research and Creative
Exchange
Senior Thesis Projects, 1993-2002

College Scholars

2002

A Genetic and Molecular Analysis of Antimicrobial Agent
Resistance in Staphylococci
Sarah E. Dodson

Follow this and additional works at: https://trace.tennessee.edu/utk_interstp2

Recommended Citation
Dodson, Sarah E., "A Genetic and Molecular Analysis of Antimicrobial Agent Resistance in Staphylococci"
(2002). Senior Thesis Projects, 1993-2002.
https://trace.tennessee.edu/utk_interstp2/88

This Project is brought to you for free and open access by the College Scholars at TRACE: Tennessee Research and
Creative Exchange. It has been accepted for inclusion in Senior Thesis Projects, 1993-2002 by an authorized
administrator of TRACE: Tennessee Research and Creative Exchange. For more information, please contact
trace@utk.edu.

A Genetic and Molecular Analysis of
Antimicrobial Agent Resistance
in Staphylococci

Sarah E. Dodson

.,-"
!

A Genetic and Molecular Analysis of Antimicrobial Agent
Resistance in Staphylococci

The intention of this paper is to characterize staphylococcal resistance to
antimicrobial agents on a genetic, molecular, and biochemical level using
seminal studies from both microbiology and molecular epidemiology as primary
references. This review is meant to be thorough, but by no means conclusive,
comprehensive, or fully complete.
Discussed initially is "classical" resistance, mediated by the enzyme plactamase. This includes enzyme structure, classification, identification,
mechanisms/kinetics of action, as well as the enzyme variants, extracellularity,
and genetics of synthesis.
Secondly, resistance NOT mediate by p-Iactams is covered, commonly
known as methicillin resistance. Included are the origin and dissemination of the
mec-resistance determinant, mec-associated DNA, and the core sequence of
mec determinant, as well as the mec regulon, PBP' function, heterogeneity in

expression of resistance and external factors affecting resistance. Also
discussed in detail are chromosomal genes affecting resistance level including
the femAB operon as well as feme, femD, femE, femF, and 11m genes. In
addition, a short summary of non mecA-mediated intrinsic resistance to plactams, BORSA and MODSA, is included.
Lastly, resistance to antimicrobial agents other than p-Iactams is
discussed. This is primarily limited to antibiotics, although resistance to organic
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cations and inorganic ions as well as antiseptics and detergents has also been
reported. Focused on are the most commonly known and used antibiotics,
including aminoglycosides, chloramphenicol, macrolides, lincosamides,
streptogramins, tetracyclines, trimethoprim and sulfonamides, fluoroquinolones,
mupirocin, and vancomycin and teicoplanin.

I.

RESISTANCE MEDIATED BY
The first

~-Iactam

~-LACTAMASE

antibiotic, penicillin, was discovered by Sir Alexander

Fleming in 1929. It was first used therapeutically in 1941, and the penicillins,
also known as the

~-Iactams,

have since been used extensively and successfully

as antibiotics in the treatment of a wide variety of bacterial infections. However,
the first report that extracts from bacteria could destroy penicillin was published
in 1940. 1 Strains of S. aureus soon emerged that were resistant to penicillin
because they were able to produce the enzyme

~-Iactamase,

called penicillinase

until 1960, which converts the penicillin into an innocuous form by hydrolysis of
the

~-Iactam

ring. Today, this form of antimicrobial agent resistance is

commonplace, particularly in strains isolated from hospital environments: there
are reports that as many as 93 percent of isolates of S. aureus are resistant to

~

lactamase-liable penicillins. 2
To overcome the failure of
underway for

~-Iactams

~-Iactam

therapy, an intensive search has been

that are not destroyed by this enzyme. This investigation

was aided by the fact discovery that benzylpenicillin could be enzymatically
deacylated to produce 6-aminopenicillinanic acid (6-APA). 6-APA was then
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treated with various acyl halides to produce a variety of semisynthetic penicillins.
Thus, it was possible to add bulky side chains to 6-APA to give, for example,
methicillin, which is only slowly hydrolyzed by the staphylococcal

~-Iactamases,
Other~

and cloxacillin, which is stable to acid and so can be given by mouth.

lactams produced include the carbapenems, such as imipenem. Cephalosporins
were also developed and some of these compounds such as cefazolin and
cephalothin are effective against

~-Iactamase-producing

S. aureus. An

extensive search was also mounted for inhibitors of the enzyme that could act in
synergy with a ~-Iactam antibiotic that would otherwise be destroyed. 3
There has also been much research into the mechanisms by which the
gram-positive staphylococci have evolved resistance to these antimicrobial
agents. It is known that gram-negative bacteria produce, between them, a wide
variety of

~-Iactamases.

Evidence indicates that the introduction of modified

~

lactams into therapy has resulted in the selection of gram-negative bacteria that
produce mutant forms of

~-Iactamase

able to hydrolyze the modified

~-Iactams.

There is no compelling evidence, however, that S. aureus has followed this route,
rather they have acquired a modified penicillin-binding protein that renders them
intrinsically resistant to

~-Iactams

such as methicillin, strains that are called

MRSA. These will be discussed in detail following this first section, resistance
mediated by

~-Iactamase,

which includes accounts of the structure, mechanisms

of action, and genetics of the staphylococcal enzyme.
There are two main systems for classifying the

~-Iactamases.

One is

based on amino acid sequence similarity and places the staphylococcal enzyme
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in Group A, along with many other

~-Iactamases

from both gram-positive and

4

gram-negative bacteria. The second system is based on the catalytic properties
of the enzyme and placed staphylococcal

~-Iactamases

in group 2a on criteria

that include the ability to more rapidly hydrolyze penicillins than cephalsporins.
Dendrograms have been constructed on the basis of sequence comparisons,
and group 2a enzymes also appear as closely related in this system;
consequently, the two distinct classification systems are seen to produce similar
groupings. 5
There are four main ways to estimate the activity of the

~-Iactamases.

The first is useful, as it can be used with crude preparations and with whole
colonies of bacteria. Iodine is used because it reacts with penicilloic acid, the
compound resulting from the cleavage of the penicillin

~-Iactam

ring, but not with

the penicillin. Secondly, a pH change that results from the action of the enzyme
can be observed, which is a good assay for purified enzyme and therefore for
detailed kinetic studies. The third method uses nitrocefin as a substrate, and
observes a color change. This method, however, is not a very good substrate for
the staphylococcal
the

~-Iactam

~-Iactamase.

Finally, differences in the absorbance between

and its hydrolysis products can be measured. These and other

methods have been reviewed, but it is rare for laboratories in hospital or health
care settings to need to carry out direct testing on staphylococci for

~-Iactamase

production. 6
Studies of the structure of

~-Iactamases

effectively began with the

determination of the arnino acid sequence of the extracellular

~-Iactamase
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purified from S. aureus PC1. This form of the enzyme consists of 257 amino
acids with a molecular weight of 28.8 kDa. The sequence has been compared
with that of several other staphylococcal

~-Iactamases

and shown to possess

four motifs that are characteristic of many enzymes interacting with ~-Iactams.
The PC1 enzyme has been crystallized and the structure determined to 2.0

A. All

four common motifs are found at the presumed active site and their relative
positions have been deterrnined by x-ray diffraction studies. There is an active
serine protease at position 70, and it is this serine that is thought to act as the
acceptor residue during the reaction. From these crystal structures and other
evidence, it is predicted that

~-Iactamases

behave like other serine proteases,

such as trypsin and chymotrypsin. In serine proteases, the oxygen of the
substrate peptide bond is in contact with the main chain-NH-groups of the two
amino acids, which, as part of the mechanism, help create an oxyanion hole.
The active site-serine is in contact with a histidine that acts as a general base to
group the serine's acylation by the -C=O group of the peptide bond. Therefore,
the peptide bond is split and an acylated enzyme is formed as an intermediate.
The histidine then acts as a general base to activate the water molecule that
hydrolyzes the serine ester to regenerate the deacylated enzyme. The two
peptide bonds are consequently released. 7
The kinetics of action of

~-Iactamases

have also been studied in depth.

When discussing this, two of the most pertinent parameters of an enzyme are kcat
and kcat I Km of kcat is a measure of the maximum number of times that an
enzyme molecule catalyzes the reaction in a unit of time, and the Michaelis
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constant (Km) is the substrate concentration at which one-half of the enzyme
molecules have substrate bound at any given time. Thus, the value of kcat / Km is
the best measure to use in comparisons of the enzyme's ability to attack
particular penicillins or cephalosporins - the higher the value, the more rapidly
the enzyme is likely to destroy the substrate. These parameters have been
determined for

~-Iactamases

for many substrates, and are regularly used to type

the variants of the enzyme, as will be discussed later.
Variants of staphylococcal

~-Iactamases

have been classified into types A,

B, C, and D on the basis of their interaction with an antiserum prepared against
purified PC1 enzyme. Types A and C are generally produced in large amounts
by S. aureus of phage-typing groups I and III, while type B is associated with
phage group II isolates. Type D was discovered to be produced by strains also
resistant to fusidic acid. The original antiserum made stimulated the activity of
type A enzymes, but is was used up, and scientists have not been able to
produce fresh antiserum that replicates the action of the original. However, the
classification has been re-determined on the basis of the differing kinetic
properties of the enzyme types. A compilation of kinetic data for the four variants
taken from Rowland et al can be seen in figure 1. Type A can best be
distinguished from types Band C by the large differences in the Km when
cefazolin is the substrate. The type A enzyme has a much higher kcat for
benzylpenicillin than that of type D. Rowland et al also found it is possible to
make these distinctions even with whole cell preparations. There are differences
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in types Band C, but they are not distinguishable by these parameters, it usually
takes testing susceptibility to inhibition by tazobactum. 8
The genes for several type A, one type C, and one type 0

~-Iactamase

have been sequenced. There are sequence differences between the type A's,
but the only major change that could account for the serological and kinetic
differences between types A and 0 is the substitution of an alanine at position
128 in the type 0 enzyme for the aspartic acid found at this position in type A.
The sequencing of the gene for the type B enzyme is currently underway.9 Most
MRSA strains produce a b-Iactanlase. A survey of 27 epidemiologically distinct
MRSA strains of S. aureus conducted during the 1960's found that all 27
produced type A ~-lactamase.1o Over 25 years later, a survey of 50 MRSA
strains from cities in the United States revealed that 40 produced type A while
the remaining 10 produced type C. No MRSA strain of S. aureus has been
shown to produce either type B or type D. 11
There is also work underway to discover whether mutations in the gene for
~-Iactamase

newer

that specify an enzyme that more efficiently hydrolyzes some of the

~-Iactams

are selected for in the natural environment. There has been

such selection found in the gram-negative

~-Iactamases,

but none has been

documented for the staphylococcal enzyme. Whether such selection is likely for
the whole culture is debatable because, if the enzyme is entirely extracellular,
and an individual bacterium would probably not be at significant selective
advantage. In contrast, staphylococci with some cell-bound
be at an advantage.

~-Iactamase

could

8
There is no good evidence as of yet that

~-Iactams

can pass across the

staphylococcal membrane. They act at the membrane surface to inhibit the
synthesis of mucopeptide, so there is no value to the organism in having a
cytoplasmic

~-Iactamase.

The enzyme is located either at the membrane or

released into the medium. Inspection of the predicted amino acid sequence at
the N-terminus of staphylococcal

~-Iactamase

revealed that for the type A

enzyme there is a leader peptide of 24 amino acids. East et al discovered that
the isolate S. aureus 1071 releases very little, if any of its enzyme into an
extracellular medium. They found a proline at position 22 of the leader peptide in
place of the serine commonly found at this position for other

~-Iactamases.

Changes they directed by site-directed mutagenesis of the serine at position 22
of the

~-Iactamase

of another isolate, 3084, that produces a large amount of

extracellular enzyme to a proline prevented the appearance of the extracellular
enzyme. 12 The leader sequence also has a motif, including a cysteine, that is
characteristic of a lipoprotein with a covalent bond to a glyceride, which is of
interest because the nucleotide sequence of a signal peptidase II, which cleaves
such lipoproteins, has been determined for a gene from S. aureus. If there is a
lipoprotein from of

~-Iactamase

in the cell membrane then it may have kinetics

that differ from those of the free form of the enzyme. 13 The advantage of such a
form to the bacterium could be that is has the potential to inactivate the antibiotic
before it reaches the sensitive site at the membrane.
For most

~-Iactamase-producing

staphylococcal, the enzyme is produced

inducibly, but the type D enzyme is produced constitutively in one strain, but
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inducibly in others. In early studies of the induction system, several regulatory
genes were identified, including the bfaf, the gene for a common repressor
protein; bfaR1, thought at that time to specify a second polypeptide that bound to
the 81al protein; and bfaR2, thought to produce a protein that could, for example,
result in the synthesis of an intracellular inducer such as a mucopeptide
precursor.

The structural gene blaZ, together with blal and blaRI, is often found

on the large plasmids whereas blaR2 is always chromosomal. The site for the

blaZ gene on the chromosome is between purB and ilvB and near agr. However,
since there is evidence for transposons containing bfaZ that may not have
specific sites for insertion and since complete plasmids are capable of integrating
into the chromosome, it is expected that the gene will be found in many different
chromosomal locations. The blaZ gene was shown to be present on the
chromosome of S. aureus PS80, but could not be transferred to a plasmid. This
was the first indication that the gene was present on a transposon; since that
time, several blaZ-containing transposons have been reported, including Tn552,
Tn4002, Tn3852, and Tn4201. These are very similar to each other and
probably have a common origin. The transposons have been shown to be
active, in that both Tn4201 and Tn3852 have been shown to translocate - the
former to a site near to, if not identical with, the site for blaZ mentioned above. 14
The complete sequence of Tn 552 has been determined, allowing
significant advances in the understanding of both the transposon and of the
regulation of

~-Iactamase

synthesis. There are six open reading frames, and

functions can be attributed to all of them. The first ORF, orf480 or transposase,

10
contains the D,D(35)E motif found in several transposases as well as in the
integrases of retroviruses. The protein has been purified and shown to bind the
termini of Tn552. The second ORF, orf251 , is probably an accessory
transposition protein, important in the selection of target DNA, thought to act in a
way analogous to the MuB protein of bacteriophage /-!. The third ORF, BinL, is a
recombinase thought to function by catalyzing recombination at the resL site
within Tn552. The fouth ORF, BlaZ, is the

~-Iactamase,

earlier, the fifth is the Blal, the classic repressor protein.

while, as mentioned
The protein binds

specifically to the blaZ operator region as shown by DNA footprinting and the
protein protects two regions corresponding to the repeats found in the operator
sequence. The protein shows 39 percent amino acid sequence identity to the
Blal protein of B. lichenformis, which has been shown to bind to the control
region for expression of

~-Iactamases

in that organism.

The sixth and final orf

is BlaR1, a putative signal transducer-sensor protein. It consists of 585 amino
acids and has homology with the BlaR1 's of B. lichenformis and methicillinresistant S. epidermidis. There are five hydrophobic regions that could span the
bacterial membrane, so that it is possible that the N-terminus is on the inside of
the membrane and the C-terminus is on the outside. The C-terminal region has
motifs found for ~-Iactam binding proteins. 15
The inducer for

~-Iactam

also binds to the C-terminal region of BlaR1,

causing a signal to be passed, either directly or indirectly to the Blal protein. The
nature of this signal is not known and it is not known whether the Blal is
covalently modified or is modified by a noncovalent interaction with a protein or
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small molecular weight effector. As a result of the signal the Blal no longer binds
to the operator region and so transcription of both blaZ and blaR11blal increases,
giving elevated synthesis of the ~-Iactamase and the regulatory proteins. 16

II.

RESISTANCE NOT MEDIATED BY

~-LACTAMASE

(METHICILLIN REISTANCE)
The primary target of

~-Iactam

antibiotics are the penicillin-binding

proteins (PBP's), enzymes anchored in the cytoplasmic membrane involved in
the last stages of peptidoglycan biosynthesis. They are responsible for the
polymerization of peptide moieties of the peptidoglycan chains, which in S.
aureus are cross-linked by a characteristic pentaglycyl side chain. Penicillin

reduces the cross-linking of the peptidoglycan and inhibits new septum initiation.
The effect of

~-Iactams

in staphylococci is dose dependent, extending with

increasing concentrations from growth inhibition, to lytic and nonlytic death. The
lethal target of

~-Iactams

has not yet been identified, and penicillin-induced death

does not necessarily coordinate with bacteriolysis. 17
Staphylococci have different means to become resistant to

~-Iactam

antibiotics. They can do so either by mutation, or more efficiently and more
clinically relevant, by acquisition of a foreign DNA element coding for methicillin
resistance. The methicillin resistance determinant mec confers to the
staphylococci an intrinsic resistance against all

~-Iactams,

including

carbapenems and cephalosporins. As stated in the introduction, the first
methicillin resistant S. aureus (MRSA) containing the mec determinant were
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isolated in 1960, shortly after the introduction of methicillin into clinical use. At
that time, MRSA compromised less than 1 percent of all isolates, but they have
since spread successfully all over the world. 18 MRSA reside mainly in
environments in which there is a constant strong antibiotic pressure, such as
hospitals. Once established, MRSA is difficult to control and eradicate.
A further property of MRSA is their tendency to accumulate unrelated
resistance determinants and incorporate them into their genome. Their
adaptability and ready response to antibiotic selection has led, in about 40 years,
to the evolution of MRSA strains resistant to almost all commonly used
antibiotics. MRSA have become a serious problem because of both their
multiresitance, and their intrinsic resistance to

~-Iactam

antibiotics, ruling out

therapy with many currently used antibiotics. Another clinically less important
class of staphylococci has appeared with borderline resistance to methicillin.
Although these isolates can sometimes be mistaken in susceptibility tests for
MRSA, they carry no mec determinant, are usually not multiresistant, and arise
by mutation at additional non-mec loci and as a result of selection for
resistance. 19
The mec determinant resides on a DNA element of more than 30 kb that is
absent in susceptible staphylococci. In all strains examined by scientists so far,
this DNA element seems to integrate at a specific site in the S. aureus genome,
between the spa (protein A) and purA (adenine requirement) genes found to be
located on the Sma-I-G fragment of S. aureus. Neither the nature or origin of this
element nor the mechanisms by which it is transferred are currently known. The
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transient capture of the mec determinant on a plasITlid by Trees and Landolo
suggest that it resides on a transposon Tn4291.2o It is believed that the early
MRSA isolates descended from one single methicillin resistance clone, however
since then, the mec determinant seems to have entered other phylogenetic
lineages of S. aureus.
It is also possible that the mec determinant was acquired at different times
by different strains and that additional mutations and deletions have served to
further diversify the mec-associated DNA as well as the genome of the host.
Clonal analysis of MRSA strains and of the mec determinant stemming from
staphylococcal species other than S. aureus, mainly S. epidermidis and S.

haemolyticus, supports the hypothesis that there may be a dissemination of the
mec determinant by horizontal transfer, with the CoNS serving as the reservoir of
the mec determinant for S. aureus.

~-Iactamases,

which are transposon and

plasmid encoded were rapidly and widely disseminated and are now widely
present in about 80 percent of all staphylococci. In contrast, the mec
determinant is still restricted to a few clonal lineages and seems to favor clonal
over horizontal spread. 21
The core sequences of the mec element consist of mecA, a gene coding
for a low-affinity penicillin-binding protein, termed PBP2' or PBP2a, which is
prerequisite of methicillin resistance, and a variable segment of 3' DNA that ends
in an insertion sequence-like element, named IS43111S257. The variable part
codes for an open reading frame that has amino acid similarity with E. coli
phosphodiesterase (UgpQ) and for a direct repeat unit (dru) containing 10
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degenerate 40-bp repeats of unknown function. The length of the fragment
between mecA and IS431 mec is hypervariable, owing to a deletion within the dru
element and postinsertional rearrangements between the IS element and the
hypervariable region. This variability is utilized for epidemiological studies, using
CIa I restriction site polymorphism of the mec determinant, or size variations after

amplification of the dru element for molecular typing of MRSA.22
Another clinically important feature, and the likely reason for the frequent
association of multiresistance with methicillin resistance, is the fact that mecassociated DNA acts as a trap for the integration of other unrelated resistance
determinants in that chromosomal segment. IS431mec thereby serves as target
for homologous recombination of other resistance determinants or plasmids
flanked by similar IS elements. Transposon attachment sites found 5' to mecA
are also responsible for the site-specification of transposon Tn554. Whereas the
mec determinant of earlier clinical isolates was stable, in more recent isolates,

which have accuITlulated more resistance determinants, and therefore contain
several direct repeats of IS43111S257, spontaneous deletions removing the mec
determinant or part of it have been observed, sometimes even deleting nearby
chromosomal genes. 23
From the more than 30 kb of additional DNA contained in the element
which is absent from susceptible strains, only a small part, namely the sequence
carrying the mecA gene, is sufficient for producing methicillin resistance in
susceptible strains. Its product is a low-affinity 76 kDa PBP2' that shows the
characteristics of a membrane-bound PBP, with a putative transglycosylase
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domain and the characteristic conserved sequences of a transpeptide. Its
transglysosylase domain is sometimes degenerated, as most ITlutational events
among different mecA genes that had no effect on the methicillin resistant
phenotype were found in the putative transglycosylase domain. The highly
conserved sequence similarity between the mecA genes of several unrelated
methicillin-resistant S. aureus and S. epidermidis strains, suggest little time has
passed since the mecA gene entered the staphylococci. 24
As stated before, the mecA origin is unknown, but it is likely that the
sequence stems from an organism with a high AT content, similar to
staphylococci. It has been proposed that the mecA sequence arose by
recombination between the promoter and N-terminal sequence of a penicillinase
gene and the structural gene of a PBP of unknown origin. Upstream of mecA,
some mec determinants contain a divergently transcribed regulatory element,
holding the genes mecR1 and mecl, separated from mecA by its promoter and
operator. mecl, the repressor of mecA, has strong similarity to Blal, the repressor
of staphylococcal p-Iactamase. mecR1 is similar to, and has the same molecular
organization, as BlaR1, which is involved in the induction of staphylococcal

P-

lactamase. It contains several hydrophobic transmembrane segments, an
extracellular penicilloyl serine transferase motif, and a cytoplasmic Zn-peptidase
motif.25
In the absence of mecl-mecR1 and p-Iactamase regulatory elements,
there is a constitutive PBP2' production. Some strains that harbor a complete
functional mecl-mecR1 regulatory element are strongly repressed and produce
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PBP2' only after induction. Induction is slow in these strains, and methicillin and
oxacillin seem to be weak inducers. Consequently, methicillin resistance is
established very slowly with full induction on methicillin-containing plates seen
only after about 48 hours. Such strains may appear falsely susceptible in
standard resistance tests. However, clinical strains that carry the sequences for
mecl and mecR1 produce PBP2' constitutively and in high amounts. They are
usually found to have point mutations or deletions that inactivate the repressor. 26
Because of their great similarity to MecR1 and Mecl, the regulatory
elements BlaR1 and Blal of the staphylococcal

~-Iactamases

can also regulate

mecA transcription. Repression by Blal is weaker than by Mecl, but there is still
some PBP2' produced in the uninduced strain, and induction by methicillin is as
rapid as

~-Iactamase

induction. Since staphylococcal

~-Iactamase

and PBP2'

share the same induction pathways, the putative chromosomal locus blaR2 that
is proposed to interfere with the bla regulon may also affect mecA regulation.
The mechanisms of the induction cascade and its components, which lead from
the extracellular

~-Iactam

to the different factors involved in signal transduction to

the final induction of either

~-Iactamase

or PBP2', remain to be found in

staphylococci. 27
It is generally believed that PBP2', which has the binding characteristics of
a normal PBP, acts as a transpeptidase, and that it takes over the functions of
the resident PBP's of the cell when activated by high concentrations of
lactams. Under normal growth conditions, in the absence of

~-Iactams,

~

PBP2'

does not seem to contribute to cell wall composition. Profound differences only
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become apparent when the normal PBP's of the cells are inactivates by ~
lactams and solely PBP2' is left functional. Whereas more than 60 percent of
muropeptides in the wall of normal growing cells are cross-linked, cross-linking
decreases to 15 percent in the presence of methicillin, suggesting that PBP2' is
restricted to the formation of muropeptide dimers only. Nevertheless, it is still
possible that PBP2' has an additional unknown role in resistance. Interestingly,
the transfer of a resistant strain that constitutively produces PBP2' from a drugfree medium to a high concentration of methicillin induces a lag period in growth
roughly proportional to the methicillin concentration in which it was placed. This
was postulated to be related to the activation of a regulatory circuit that switches
cell wall synthesis from the normal PBP's to PBP2' .28
Besides studying the PBP's of staphylococci, much research has gone
into the heterogeneous expression characteristic of the methicillin-resistant
strains. When an overnight culture of a MRSA strain is plated on increasing
concentrations of methicillin or on any other

~-Iactamase

resistant

~-Iactam

and

the colony-forming units are determined, only a small fraction of the total
population is able to grow at much higher concentrations than the majority. The
concentrations up to which most of the cells grow is commonly called the basal
resistance level. 29 There have been observations that the population analysis
profile is also growth phase dependent, which suggests that whatever changes
are triggered by methicillin that allow resistance above the basal level are cell
cycle dependent. In some strains, the highly resistant subpopulation will keep
the high resistance once it has been formed, and descendents of this
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subpopulation will remain resistant to those concentrations of methicillin to which
they were selected. The stability of these subclones suggests that they may also
be mutants. On the other hand, in some clinical isolates, the subclones return to
their original resistance upon regrowth from a single colony in drug-free medium.
This could be explained by assuming that the initial level of resistance was due to
the induction of methicillin resistance and that induction was lost upon regrowth
on drug-free medium, demonstrating the different mechanisms that may lead to
high resistance.

30

Clinical isolates carrying the mec-determinant vary widely in their basal
resistance to methicillin (MIC's of less than 4 ug/ml to greater than 1,000 ug/ml),
as well as in the ratio of cells able to develop high methicillin resistance. Since
population profiles are a strain-specific property that can be reproduced under
strictly controlled conditions, clinical isolates have been arbitrarily divided into
four classes of expression by Tomaz et ai, although it is not clear that each of
these classes corresponds to a single mec/host background. 31 Despite many
efforts such as this, there currently exists no satisfactory model that can explain
the mechanisms governing heteroresistance. Rearrangements involving the
mec determinant have been observed in strains after selection for high methicillin
resistance, but they were shown not to be responsible for increased resistance. 32
Slow inducibility of mecA when controlled by a strong repressor, as in strains with
mecR1-mec/, can lead to low resistance. It has also been shown that repression

of mecA by the

~-Iactamase

repressor turns a highly and homogeneously

resistant MRSA into a heterogeneously resistant strain, when the corresponding
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signal transducer, needed for induction (BlaRI) is inactivated. 33 This means that
a certain threshold of PBP2' is needed for the expression of methicillin
resistance. However, in strains with constitutive PBP2' synthesis, which vastly
overproduce this protein, the same amount of PBP2' is present whether the cells
are heterogeneously or homogeneously resistant. A number of studies have
been unable to establish a correlation between the amount of PBP2' production
and resistance levels, suggesting that other genes cooperate with PBP2'.

34

In contrast, a series of experiments showed that a chromosomal gene(s),
termed chr*, was responsible for the expression of high level resistance, and that
neither mecA nor any of the additional mec-associated DNA was involved. A
similar conclusion, namely that the chromosomal background of the
staphylococcal strain plays an important role in determining resistance levels,
was drawn from another experiment. Homogeneous high-level methicillin
resistance was abolished by insertional activation of mecA. Methicillin resistance
could be restored to its original high resistance level by reintroducing mecA even
though its gene came from a low-level heterogeneously resistant strain. The
functions of genes involved in high-level methicillin resistance such as chr*
remain to be identified, however a chromosomal segment that may mediate highlevel resistance was recently cloned. Characterization of genes such as this may
help clarify the differential expression of resistance.

35

External factors, such as temperature, pH, osmolarity, light, divalent
cations, chelating agents, and anaerobiosis can also affect methicillin resistance.
Lowering the temperature and increasing NaCI concentrations enhances
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methicillin resistance, and these conditions are routinely employed in the
detection of methicillin resistance in clinical isolates. However, which genetic
elements respond to these external factors in staphylococci and how they are
connected to the methicillin resistance are still unknown.36
Signal transduction may also play an important role in methicillin
resistance. Substances that are able to interact with the cell membrane, such as
surfactant glycerol monolaurate, were shown to inhibit

~-Iactamase

induction,

probably by interfering with signal transduction. The detergent Triton-X1 00,
which stimulated both the release of acylated lipoteichoic acids and bacterial
autolysis, was shown to reduce methicillin resistance when added in
subinhibitory concentrations. The effect is similar to that of polidocanol, a
nonionic detergent, which has been shown to increase the susceptibility of MRSA
to ~-Iactam antibiotics. 37 These substances presumably act at the cell
membrane level, disturbing signal transduction and enhancing

~-Iactam

action by

interfering with cell wall metabolism. Mutants resistant to these effects might
help identify additional factors involved in

~-Iactam

action and resistance.

Tn551-mediated insertional mutagenesis of the staphylococcal genome
has been used to generate susceptible mutants from a methicillin resistant strain.
The genes identified were termed factors essential for methicillin reistance (fern)
or auxiliary (aux) factors. These Tn551-mediated inserts were then mapped and
found to be numerous and scattered around the staphylococcal genome.
According to the effect of their inactivation on methicillin resistance, they can be
separated into two classes. Inserts in femA and femB abolish methicillin
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resistance completely, including even the formation of a highly resistant
subpopulation. Other factors, such as feme and femD, reduce the basal
resistance level but still allow formation of highly resistant revertants. All of these
factors belong to the normal set of genes of the staphylococcal genome of both
susceptible and resistant strains and are involved directly or indirectly in specific
steps of cell wall biosynthesis. Inactivation of these factors in a susceptible strain
results in hypersusceptibility to ~-lactams.38
The femAB operon was mapped downstream or trpA in the Sma I-A
fragment in S. aureus 8325. It is involved in the peptidoglycan pentaglycine
interpeptide bridge formation. Mutants that lack FemS are able to attach only
three glycines to the cross-bridge. No femA zero mutant is available, but
peptidoglycan composition of a polar mutant allowing less than 10 percent of

femAB transcription suggests that FemA directs incorporation of glycines two and
three. The first glycine appears to be added independently of FemA and
FemS. 39 The precise role of these two cytoplasmic proteins, which are very
similar to one another and have an approximate size of 49kDa, is unknown. The
glycines are added to the peptidoglycan stem-penta peptide by three glycyltRNA's that are specific for cell wall synthesis and different from the glycyl-tRNA
used in protein biosynthesis. In S. aureus, glycine is loaded on each of these
tRNA's by a single glycyl t-RNA synthetase. However, FemA and Fen1S lack
homology to any published protein sequences, including glycyl t-RNA
synthetase. Therefore, it is not possible to predict their precise functions.

4o
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The long flexible pentaglycine side chain is responsible for the high crosslinking values characteristic of the staphylococcal peptidoglycan. The shortened
glycine side chain in femAB mutants leads to reduced peptidoglycan crosslinking and to higher resistance to lysostaphin, a glycyl endopeptidase.
Additional defects in femAB mutants include aberrant septum formation,
thickened cross walls, and a retarded cell separation. Neither PBP2' synthesis
nor that of the normal PBP's is affected in femAB mutants. PBP's are produced
in normal amounts, but their function is impaired - the cells become
hypersusceptible to

~-Iactams.

This is clinically significant because inhibition of

FemA of FemB to any antibacterial agent should therefore restore the efficacy of
~-Iactams

against MRSA.

The feme and femO loci were also found to be located on the
chromosomal Smal-A fragment of the S. aureus 8325 chromosome. Inactivation
of feme reduces only the basal resistance level in MRSA but still allows
formation of a highly resistant subpopulation. The feme mutation produces a
metabolic block in glutamine production. Inactivation of the glutamine synthetase
repressor (glnR) has a polar effect on transcription of the 3' glutamine synthetase
gene, gInA, in the glnRA operon, leading to reduces production of glutamine
synthetase and consequently to a lack of glutamine. This has an indirect effect
on peptidoglycan composition, reducing the degree of cross-linking in the
peptidoglycan. Addition of glutamine to the growth medium can restore
methicillin resistance. The mutation femO interferes with peptidoglycan
precursor production. It has been postulated to be a defect in a gene controlling
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the rate of biosynthesis of the unsubstituted disaccharide pentapeptide
precursor.

41

Little information is available on femE, although it has been identified as a
Tn551 insertion in the Smal-A fragment, in a site distinct from femAB and feme.
No significant changes in peptidoglycan composition were detected in this
mutant. 42 femF mutants are impaired in an early step of precursor muropeptide
synthesis and the gene has been localized to the Smal-B fragment. 43
In addition to the fern (factors associated with methicillin resistance), a
gene, 11m, coding for a 38-kDa lipophilic protein, has been identified that
increases autolysis rates and reduces methicillin resistance upon inactivation, as
do the fem factors. The 11m gene has been identified in all S. aureus strains, but
has not been found in other staphylococcal species. 11m shows strong similarities
to mra Y, the first enzyme involved in the lipid cycle of peptidoglycan
biosynthesis. 44 From the growing list and functions of fem factors, it seems that
any disturbances in the well-balanced biosynthesis of peptidoglycan and possibly
alterations in membrane composition as well, reduce the optimal function of
PBP2' when resident PBP's are saturated by methicillin. As previously stated,
the fem factors seem to belong to the normal housekeeping genes of
staphylococci and apparently function normally in clinical methicillin-resistant
isolates. Although their experimental disruption by transposon insertion leads to
a reduction in methicillin resistance, it is not clear that any of the fem genes or
loci are directly involved in the expression of methicillin resistance in clinical
isolates or that they are altered in their expression or function by the presence of
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the mec determinant. Future studies could possible use techniques other than
gene inactivation to find these resistance-associated factors.
Unlike the femAB mutants, the femC, femO, and 11m mutants produce a
small number of highly methicillin-resistant revertants when plated on high
concentrations of methicillin. Reversion takes place in a site distant from the
corresponding fem or 11m mutation. In femC mutants, this reversion affects an
unidentified gene(s), termed hrmC (for high methicillin resistance reversion in

femC), and does not restore the glutamine synthetase activity. The
corresponding hmrO revertants of femO and the highly resistant revertants of 11m
likewise occur at sites involving neither femO nor 11m. These revertants are
highly and homogeneously resistant, similar to the highly resistant subpopulation
formed by a heterogeneous MRSA in the presence of high concentrations of
methicillin. However, the chromosomal chr* mutation involved in high-level
resistance of wild-type MRSA strains could not substitute for the hmrC mutation.
This means that in MRSA, rnultiple paths may lead to high-level resistance. 45
Standard susceptibility tests sometimes fail to distinguish between an
MRSA with a very low level basal resistance and the clinically less relevant
borderline resistant strains mentioned earlier that carry no mec determinant.
Two types of borderline resistant strains have been encountered: BORSA and
MODSA. The first type, termed BORSA, are hyperproducers of

~-Iactamase

or

strains specifically producing a methicillinase. This resistance mechanism is not
intrinsic because it involves partial hydrolysis of penicillinase-resistant penicillins.
However, it appears that their hyperproduction of

~-Iactamase

is not sufficient,
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and that specific, yet-to-be defined host background factors are also needed to
establish borderline resistance. 46
The second type of borderline resistant isolates, termed MODSA, are
strains with modifications in their own PBP's. Such strains can also be obtained
in vitro from a susceptible S. aureus and selected for growth on increasing
concentrations of ~-Iactams. Multiple factors that have yet been identified are
involved in this process, and changes in the amount and/or affinity of the existing
PBP's of the cells have been described. Increase in resistance by this
mechanism is usually impaired with decreasing growth rates. In contrast to
mecA-dependent methicillin resistance, no heteroresistance is observed in
MODSA strains

all descendents of the culture are uniformly resistant. 47

Clinically, neither the BORSA nor the MODSA have become as relevant as
MRSA but, because of their phenotypic overlap with low-level resistant MRSA,
identification methods have been used that can distinguish between the
presence or absence of the mecA gene.
In April 2001, Kuroda et al publishes the genome sequence (about 2.8
million base pairs) for two strains of MRSA, Mu50 and N315. 48 Many believe this
is the breakthrough needed to finally begin to "win" the struggle against MRSA.

III. RESISTANCE TO ANTIMICROBIAL AGENTS OTHER THAN

~-LACTAMS

Resistance to a wide range of antimicrobial agents, including antibiotics,
antiseptics/disinfectants, and inorganic or heavy metal ions, has been reported in
S. aureus and other staphylococci. 49 In many instances, the resistance elements
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are either plasmid-encoded or associated with other mobile genetic elements.
These determinants mediate resistance through a number of different
biochemical mechanisms that can be classified into several common categories:
inactivation mechanisms, bypass mechanisms, target site alteration, efflux
mechanisms, and sequestration.

In the first example, the antimicrobial agent is inactivated by chemical
modification by either intracellular or extracellular detoxifying enzymes (e.g. the
inactivation of chloramphenicol by chlorarnphenical acetyltransferase).
Secondly, staphylococci can bypass the effect of the antimicrobial agent by
substitution of an alternate pathway or enzyme, as in resistance to trimethoprim
due to the synthesis of an alternative trimethoprim-insensitive dihydrofolate
reductase enzyme. Thirdly, target site alteration leads to a reduced affinity of the
target site for binding with the antimicrobial agent, as is observed with in
resistance to macrolides, lincosmaides, and streptogramin (MLS) type B
antibiotics, where there target site is structurally modified (methylation of the 23S
rRNA adenine residues). Fourthly, the antimicrobial agent can be actively
pumped out of the bacterial cell (e.g. the active export of toxic organic cations).
Lastly, the antimicrobial agent can be specifically and stoichiometrically bound by
a cellular protein such that its antimicrobial action is blocked, an example of
which can be seen in the binding and sequestration of bleomycin. Some of these
examples and others will be discussed in detail in the next sections. 50 For each
antibiotic, examples of each will be given along with their mechanism of action
and prevalence of use for staphylococcal infections. Also discussed will be
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cloning and sequence analysis of proposed resistance determinants, location
(where they are located chromosomally, types of plasmids, etc), and homology to
other known determinants, as well as other factors relevant to describing the
genetic and molecular bases of resistance.
AMINOGLYCOSIDES
Aminoglycoside antibiotics, including gentamicin, kanamycin,
streptomycin, and neomycin, inhibit protein synthesis by binding to the 30S
ribosomal subunit. Aminoglycosides have been widely used to treat
staphylococcal infections and are still used in combination with other
antistaphylococcal agents. The major mechanism of aminoglycoside resistance
observed in the staphylococci is drug inactivation by cellular enzymes, such as
aminoglycoside acetyltransferases (AAC), adenyltransferases (AAD), or
phosphotransferases (APH). Aminoglycosides modified at the amino groups (by
AAC's) or hydroxyl group (by AAD's or APH's) lose their ability to bind
ribosomes, and hence, do not inhibit protein synthesis. 51
Resistance to gentamicin and concomitant resistance to tobramycin and
kanamycin in the staphylococci is mediated by a bifunctional enzyme displaying
both AAC And APH activity, which has been purified and characterized
biochemically.

52

The aacA-apdD gene encoding this enzyme has been cloned

from the plasmid pSK1 and sequenced. Amino acid sequence analysis suggests
that it contains two separate domains, an N-terminal domain with homology to
AAC enzymes and a C-terminal domain with homology to APH enzymes.
Mutagenesis of the aacA-apdD gene supports the notion that two separate
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domains in this enzyme are responsible for the two aminoglycoside-modifying
activities. The aacA-apdD gene has been shown to be encoded on the
composite transposon Tn4001. Tn4001 and Tn4001-like elements have been
found to be widely distributed in both S. aureus and CoNS, being found on pSK1
family plasmids, conjunctive plasmids, occasionally on p-Iactamase/heavy metal
resistance plasmids, and also in various chromosomallocations. 53
Resistance to neomycin, kanamycin, tobramycin, and several other
aminoglycosides in the staphylococci is mediated by an AAD encoded by the
aadD gene. The aadD gene is often carried on small plasmids, such as pUB11 O.
The complete nucleotide sequence of pUB11 0 has also been determined, and
the AAD product of aadD has been purified and biochemically characterized.
Copies of the aadD-encoding pUB11 O-like plasmids have also been found
integrated into large conjunctive plasITlids and into the methicillin resistance mec
region of the chromosome of some S. aureus isolates. Additionally, a variety of
other plasmids encoding AAD have been detected and probably also carry an
aadD gene. 54
Staphylococcal streptomycin-resistance genes have also been identified.
Sequencing of the streptomycin resistance gene str, identified on small plasmids
such as pS 194, has demonstrated that its product is homologous with AAD
enzymes fron1 other bacteria. High-level streptomycin resistance has been
associated with chromosomal mutations (strA) that affect the ribosome. Lowlevel cross-resistance to most aminoglycosides appears to be due to a
chromoson1al mutation that affects the membrane's permeability to
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aminoglycosides. A streptomycin resistance APH encoded by an aphC gene has
also been found in S. aureus, but not well characterized. Additionally, a plasmidborne aadA gene encoding an AAD that confers resistance to streptomycin and
spectinomycin has been detected. 55
CHLORAMPHENICOL
Chloramphenicol is a bacteriostatic antibiotic that binds to the 50S
ribosomal subunit and inhibits the transpeptidation step in protein synthesis. It
has not been widely used as an antistaphylococcal agent, however resistance to
chloramphenicol in the staphylococci has been reported and is due to the
inactivation of the antibiotic by a chloramphenicol acetyltransferase enzyme
(CAT), which acetylates the antibiotic. 56 cat genes have been located on a wide
variety of staphylococcal plasmids, and three main families of cat-encoding
plasmids have been identified, typified by the plasmids pC194, pC221, and
pC223. The nucleotide sequences of the cat genes on S. aureus plasm ids such
as these have been determined and their products are homologous both with
each other and with cat enzymes from other bacteria. Expression of the cat gene
is typically inducible and has been studied in detail in the case of the pUB112 cat
gene. Expression seems to be regulated by translational attenuation in a similar
manner to ermC expression, which will be discussed in the next section.

The

cat gene is preceded by a 9-amino acid leader peptide, and the leader mRNA

can form a stable stem-loop structure, which masks the ribosome binding site of
the cat gene. Chloramphenicol appears to cause the ribosome to stall on the
leader sequence, opening the stem-loop structure, thereby exposing the cat
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ribosomal binding site, allowing cat expression, and therefore resistance to
chloramphenicol. 57
MACROLIDES, LlNCOSAMIDES, STREPTOGRAMINS (MLS)
Macrolides, such as erythromycin and oleandomycin; lincosamides, such
as lincomycin and clindamycin; and streptogramin antibiotics have a
bacteriostatic effect sin1ilar to that of chloramphenicol - by binding the 50S
ribosomal subunit and arresting protein synthesis. Erythromycin, clindamycin,
and lincomycin have been used extensively in the treatment of both minor and
major staphylococcal infections. Currently, resistance to these agents is highly
prevalent among the staphylococci.

Streptogramins, such as pristinamycin,

have been used in Europe as antistaphylococcal agents, but the prevalence of
resistant strains remains

IOW.58

A number of determinants conferring resistance

to this group of antibiotics via a variety of mechanisms have been identified in the
sta phylococci.
Three homologous staphylococcal determinants, ermA, ermB, and ermC
have been identified that confer resistance to the MLS antibiotics by target-site
alteration of the ribosome. The best example of these genes, ermC, has been
demonstrated to encode a methylase, which catalyzes the dimethylation of an
adenine residue in the 23S ribosomal subunit, thereby reducing the affinity
between the ribosome and the MLS antibiotic. The ermC gene is typically carried
on small staphylococcal plasmids, such as pE194, and its expression is inducible
and is regulated at the level of mRNA secondary structure, as has been thought
for cat regulation. The ermC mRNA contains a leader sequence coding for a 19-
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amino acid leader peptide, and this leader mRNA is capable of forming a stable
stem-loop structure that sequesters the ermC binding site. Erythromycin-induced
stalling of the ribosome during translation of the leader sequence opens up the
stem-loop, permitting ribosomal access to the ermC ribosomal binding site and
subsequent translation of ermC. Both genetic and physical evidence strongly
support this model of translational attenuation and have suggested that codons 5
to 9 of the leader sequence are essential for induction while codons 9 and 10 are
in physical contact with the stalled ribosome. Although ermC-encoded MLS
resistance is characteristically inducible, both naturally occurring and in vitro
mutants of ermC have been isolated that express constitutive MLS resistance. 59
The ermA gene also confers inducible resistance to MLS and has been
shown to be encoded on the transposon Tn554. Tn554 also carries the
streptomycin resistance spc gene encoding an adenyl transferase, similar to AAD
of aminoglycoside-resistant strains. The cornplete sequence of Tn554 has been
determined and the ermA gene demonstrated to encode a product homologous
to the RNA methylase encoded by ermC. Tn554 has been shown to insert at a
specific site in the S. aureus chromosome but has also been found at a number
of chromosomal sites, including within the mec region and may also be plasmid
located. The ermA gene is preceded by a leader sequence coding for a 19
amino-acid peptide homologous with the ermC leader peptide. This suggests
that ermC is also regulated by translational attenuation; supporting this,
erythromycin-induced stalling of the ribosome on the ermA leader has been
observed. Erythromycin may also playa role in stabilizing the ermA mRNA.
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The ermB gene confers constitutive resistance to MLS and has been
detected on some ~-Iactamase/heavy metal plasmids where it is encoded on the
transposon Tn551. Transposition of Tn551 has been demonstrated in vivo and
the transposon has been partially sequenced at this time.

60

Distinct from the erm genes, msrA gene confers resistance only to 14-and
15-member macrolides, such as erythromycin, and to type B streptogramins,
possibly by an efflux mechanism. msrA is frequently plasmid encoded and is
widely disseminated in clinical S. epidermidis strains, as well as being found in S.
aureus strains. msrA has been cloned and sequenced from the S. epidermidis

plasmid pUL5050 and found to encode a hydrophobic protein with sequence
similarity to the ATP-binding components of the ABC superfamily ATP-dependent
transport systems. The region upstream of msrA resmbles the control regions of
ermAIC genes regulated by translational attenuation. 61 Epidemiologic studies of

erythromycin resistance have indicated that ermC and msrA are the most
frequent causes of erythromycin resistance and that ermA and ermB are only
present in a minority of isolates. 62
TETRACYCLINES
Tetracycline and related antibiotics are bacteriostatic agents that bind to
the 30S ribosomal subunit, preventing stable association with the aminoacyltRNA, resulting in the inhibition of protein synthesis. Tetracycline is a very
commonly used antibiotic, but has not been widely used for treatment of
staphylococcal infections, however a semi-synthetic tetracycline, minocycline, is
used in some countries for treatment of multi-resistant staphylococcal strains. 63
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Two different resistance mechanisms to tetracycline have been identified in the
staphylococci. First, the chromosomally encoded tetA(M) gene confers
resistance to tetracycline and to semisynthetic analogues, including minocycline,
by a mechanism known as ribosomal protection. The tetA(M) gene from a
clinical S. aureus isolate has been cloned and sequenced and found to share a
high level of sequence sirrlilarity at the nucleotide and amino acid level with class
M tet determinants from other gram-positive and-negative organisms. Southern
hybridization analysis has suggested that there is no indication that tetA(M) in S.
aureus is located on a transposable element. Expression of tetA(M) gene has

been shown to be induced by the tetracycline. The TetM protein shares
sequence sirrlilarity with elongation factor G, which translocates the peptidyltRNA during protein synthesis, and other GTP-binding proteins. tRNA
modification activity has been suggested to be necessary for TetM-mediated
tetracycline resistance, but to date, the biochemical basis remains unclear. One
possibility is that TetM stabilizes the ribosome-tRNA interaction in the presence
of tetracycline. 64 ,65
The second tetracycline resistance mechanism identified in staphylococci
is active efflux that can be encoded by either of to determinant tetA(K) or tetA(L).
Both confer inducible resistance to tetracycline, but not its semisynthetic
analogues. tetA(K) is found on small plasmids, and also has been found
chromosomally due to IS257-mediated integration of a plasmid. tetA(K) has
been cloned an sequenced from staphylococcal plasmids. tetA(L) is also
typically found on small plasm ids in Bacillus sp., but it also has been seen in
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staphylococci. Both tetA(K) and tetA(L) are probably regulated by translational
attenuation in a similar manner to that of cat, ermA, and ermC expression. The
products of tetA(K) and tetA(L) are homologous to each other, as well as to a
range of drug efflux proteins in the major facilitator superfamily, some of which
are discussed later. TetK and TetL are both thought to be membrane proteins
with 14 transmembrane-spanning segments. Like other members of the major
facilitator superfamily, TetK and TetL mediate drug efflux driven by the proton
motive force (pmf) of the transmembrane electrochemical proton gradient, rather
than by ATP hydrolysis. Transport assays have indicated that tetK confers
tetracycline resistance - assays of tetracycline uptake in everted membrane
vesicles have indicated that TetK is functionally similar to the well-characterized
TetB tetracycline efflux pump encoded in enterobacteria. In a similar manner to
TetB, TetK-mediated tetracycline efflux was demonstrated to be dependent on
the presence of divalent cations, such as Co 2 +, which are co-transported with
tetracycline - transport of such a metal ion/tetracycline complex is coupled with
proton transport. 66
TRIMETHOPRIM AND SULFONAMIDES
Trimethoprim and the sulfonamides are synthetic agents that affect the
biosynthesis of hydrofolic acid, an essential derivative used in amino acid and
nucleotide synthesis. Sulfonamides are analogues of p-aminobenzoic acid that
competitively inhibit the enzyme dihydropteroate synthase (DHPS), which
catalyzes the condensation of dihydropteridine with p-aminobenzoic acid, an
early step in tetrahydrofolic acid synthesis. Trimethoprim is an analogue of
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dihydrofolic acid that competitively inhibits the enzyme dihydrofolate reductase
(DHFR). DHFR catalyzes the reduction of dihydrofolic acid to tetrahydrofolic
acid, the final step of tetrahydrofolic acid synthesis. Cotrimoxazole, a
combination of trimethoprim with a sulfonamide, has been used extensively to
combat staphylococcal infections. 67
Both high- (MIC greater than 1,000 j.tg/ml) and low- (MIC less than 100

j.tg/ml) level trimethoprim resistance has been reported in both S. aureus and
CoNS. In some cases, chromosomally encoded low-level trimethoprim
resistance may be due to overproduction of host DHFR. More commonly,
however, resistance is encoded by the dfrA gene carried on the transposon-like
element Tn4003. dfrA codes for a trimethoprim-resistant type S 1 dihydrofolate
reductase that has been both biochemically purified and characterized. Tn4003
has also been sequenced and it or similar dtiA encoding elements have been
found on pSK1 family plasmids, large conjunctive plasmids, and on various other
plasmids in both S. aureus and CoNS. Transposition of Tn4003 has not been
experimentally demonstrated; rather, its apparent motility may be due to IS257mediated recombination events. The dtiA gene appears to be responsible for
both high- and low-level resistance to trimethoprim in both S. aureus and CoNS.
The differences in resistance correlate with differences in transcription caused by
deletions adjacent to a copy of IS257 in Tn4003 affecting the promoter used by
dtiA.68

The chromosomal trimethoprim-sensitive DHFR gene from S. aureus has
been cloned and sequenced and found to be distinct from dtiA (80 percent
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identical at the amino acid level) and not located within an operon, suggesting
that drfA did not originate from the S. aureus chromosomal DHFR gene. In
contrast, the S. epidermidis trimethoprim-sensitive chromosomal DHFR gene
differs from drfA by only 4 bp and is found in an operon-like structure, strongly
suggesting that drfA originate from the S. epidermidis chromosomal gene. Sitedirected mutagenesis of drfA and kinetic analyses of purified DHFR's has
indicated that a single alteration is largely responsible for the trimethoprim
resistance. 69
FLUOROQUINOLONES
Fluoroquniolones such as norfloxacin, ciprofloxacin, and pefloxacin are
synthetic broad-spectrum antimicrobial agents that interfere with the function of
DNA gyrase, an essential enzyme involved in DNA replication and repair.
Fluoroquinolone resistance has arisen rapidly in the staphylococci following the
use of these agents in recent years to treat both gram-positive and gramnegative bacterial infections. Three distinct loci have been identified in S. aureus
that are involved in conferring resistance to fluoroquinolones. 7o
First, target alterations in DNA gyrase can decrease the fluoroquinolone
sensitivity of this enzyme. DNA gyrase is a tetrameric enzyme with two subunits
(A and B) encoded by the gyrA and gyrB genes, which are homologous to their
counterparts from other bacteria such as E. coli and B. subtilis. Sequencing of
rnutant alleles of gyrA from a very large number of independent fluoroquinoloneresistant isolates has indicated that mutations conferring fluoroquinolone
resistance are located within a single region near codon 84. Additionally, gyrB
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mutants have been identified that confer lower levels of resistance than gyrA
mutants. These mutants were found to have substitutions at codon Asp-437 or
Asp-458. Transformation of these gyrA or gyrB fluoroquinolone-resistant
mutants with wild type gyrA or gyrB plasmids reconferred fluoroquinolone
susceptibility in these strains, confirming that mutations in gyrA and gyrB are in
fact responsible for the fluoroquinolone resistance. In addition, purified DNA
gyrase from fluoroquinolone-resistant gyrA mutants has been shown in vitro to be
resistant to approximately 20-fold higher concentrations of the agent than purified
wild-type enzyme from fluoroquinolone-sensitive strains. 71
Secondly, low-level fluoroquinolone resistance appears to be associated
with mutations in the chromosomal grlA gene of S. aureus. The S. aureus grlA
and grlB genes encode for homologues of GyrA and GyrB, which have been
demonstrated to catalyze ATP-dependent DNA relaxation. Analysis of
fluoroquinolone-resistant S. aureus mutants has indicated that mutants resistant
to low levels of fluoroquinolone contained substitutions at Ser-80 of GrIA. Work
with stepwise-selected mutants has indicated that mutations in grlA are required
for expression of resistance due to gyrA mutations. Thus, low-level resistance is
conferred by grlA mutations, but high-level resistance is a result of mutations in
both grlA and gyrA. Thirdly, a chromosomally encoded active fluoroquinolone
efflux system encoded by the norA gene has been described in S. aureus. The
norA gene has been cloned and sequenced and found to encode a membrane
protein. Sequence analyses have indicated that NorA is a member of the major
facilitator superfamily of transporter proteins and is closely related to other drug
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efflux proteins, some of which were mentioned earlier. Drug transport studies in
whole cells and everted nlembrane vesicles have indicated that NorA mediates
the active efflux of fluoroquinolone driven by the pmf. norA has also been shown
to confer resistance to a range of compounds structurally unrelated to the
fluoroquinolones and the norA gene has also been found in fluoroquinolonesensitive staphylococcal strains. An initial report suggested that fluoroquinolone
resistance was due to a single base pair change in norA, resulting in a single
amino acid change in its product. However, sequencing of the complete norA
gene from both sensitive and resistant S. aureus strains failed to detect any
differences within the gene?2
MUPIROCIN
The antibiotic mupirocin (pseudomonic acid A) is an isoleucine analogue
that competitively inhibits isoleucyl-tRNA synthetase (IRS), preventing protein
synthesis. Mupirocin has been used as a topical agent in the treatment of grampositive bacterial infections since its introduction in 1985. Interestingly, mupA
has been detected in staphylococcal strains dating from 1965, well before the
introduction of mupirocin as a topical agent. High- (MIC greater than 1,000
J.lg/ml) and low- (MIC 8 to 256 J.lg/ml) resistance to mupirocin has been detected
in both S. aureus and CoNS. Low-level resistance is probably due, in most
cases, to mutation in the host IRS.73 Strains resistant to high levels of mupirocin
have been shown to contain two biochemically distinct IRS enzymes: the na'lve
mupirocin-sensitive IRS enzyme and an additional IRS enzyme that is less
sensitive to inhibition by mupirocin. The mupA gene that codes for a mupirocin-

39

resistant shares significant sequence similarity with a number of different
bacterial IRS enzymes and contains characteristic IRS-specific motifs involved in
ATP hydrolysis and amino acid activation. The mupA gene is, however, distinct
from the chromosomal IRS gene, as they share only 30 percent similarity at the
amino acid level. Thus, high-level mupirocin resistance in S. aureus appears to
be due to the acquisition of an IRS gene from another organism, possibly in an
analogous manner to the acquisition of trimethoprim resistance, as discussed
previously. The mupA gene has demonstrated to be plasmid encoded in a rage
of epidemiologically independent S. aureus and CoNS strains. Analysis of the
mupA plasmids of pG0400 and pl3358 has indicated that the gene is flanked by
directly repeated copies of the insertion sequence IS257. Analysis of other
staphylococcal plasmids has suggested that IS257 has played a role in horizontal
transmission of the resistance gene, as was suggested for previous examples. 74
VANCOMYCIN AND TEICOPLANIN
Glycopeptide antibiotics, such as vancomycin and teicoplanin, form
complexes with the peptidyl-o-Ala-o-Ala terminus of the peptidoglycan precursors
at the outer surface of the cytoplasmic membrane, leading to the inhibition of
transglycosylation and transpeptidation steps of cell wall synthesis. Since the
development of multiresistance staphylococcal strains, vancomycin has
frequently been the only drug available to the clinician for the treatment of
serious infections caused by MRSA. Staphylococcal strains with reduced
susceptibility to both vancomycin and teicoplanin have been isolated. In clinical
strains of CoNS, resistance to both has also been noted, although more
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commonly, strains are resistant to teicoplanin (MIC less than 128 }lg/ml) but
sensitive to vancomycin (MIC less than 4 }lg/ml). In particular, S. haemo/yticus
displays a propensity for developing resistance to glycopeptides in a single step
upon exposure. Clinical isolates of S. aureus have been detected which have
low-level resistance to both vancomycin and teicoplanin, while mutants of

S.aureus have been selected in vitro with decreased susceptibility to both as
well?5

A number of studies of glycopeptide-resistant staphylococcal strains

have indicated that resistance is typically constitutively expressed,
chromosomally encoded, and is stable in the absence of selective pressure.
Clinical isolates of teicoplanin resistant staphylococci have been found to
express a 39-kDa protein associated with the membrane to cell wall of the
organisms. Kaatz et al detected a teicoplanin-resistant isolate from a single
patient following unsuccessful therapy. Tn551 insertion mutants obtained of this
strain regained teicoplanin susceptibility. These insertions were mapped to a
single Sma1 chromosomal fragment. Analysis of the resistant strain indicated
that expressed a 35-kDa membrane protein and had increased expression of
both PBP2 peptides relative to the Tn551 insertion mutants. Moreover, its cell
wall physiology was altered in some aspects.?6 In a similar study, analysis of
clinical S. aureus isolates with decreased susceptibility to vancomycin from 12
patients indicated that the majority expressed a 35-kDa membrane protein with
increased expression of both PBP2 peptides as well.??
Vancomycin- and teicoplanin-resistant S. aureus mutants have been
obtained in vitro by serial incubation in the presence of a low concentration of
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either compound. Daum et al isolated mutants exhibiting low-level vancomycin
resistance that showed alterations in cell wall organization and constitutively
produced a 35-kDa protein. The ddh gene encoding this protein has been cloned
and sequenced and codes for a cytoplasmic protein with sequence similarity to

0-

lactate dehydrogenase (o-LDH) and to the enterococcal VanH protein (discussed
later). ddh was shown to be expressed in wild-type staphylococci, and
expression was found to be increased in a glycopeptide-resistant mutant, which
was associated with increased o-LDH activity. This possibly suggests that
overexpression of o-LDH in S. aureus may contribute to low-level glycopeptide
resistance. As mentioned earlier, decreased susceptibility to glycopeptides in
the staphylococci also appears to be associated with expression of a 35- or 39kDa membrane protein, often accompanied by increased expression of PBP2
peptides and apparent alterations in the cell wall physiology of the organism.
Despite the similarity in size, these 35- or 39-kDa proteins probably do not
correspond to Ddh, as Ddh is a cytoplasmic protein. Therefore, the
mechanism(s) of glycopeptide resistance in these strain(s) still remain to be
clarified. 78
In the better-studied enterococci, transferable high-level resistance to
vancomycin (MIC greater than 512 J.lg/ml) with concomitant resistance is
commonly seen and is referred to as VanA type resistance. This phenotype has
been shown to be encoded by the vanA gene cluster on the 10.8 kb transposon
Tn 1546, which is often carried by conjunctive plasrnids with a broad host range in
gram-positive bacteria. Tn 1546 includes three genes essential for glycopeptide
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resistance: vanA, which encodes an alternative o-Ala-o-Ala ligase that produces
altered peptidoglycan side chains, containing an terminal dipeptide (e.g. o-Ala-olactate) with greatly reduced affinity for glycopeptide antibiotics; vanH, which
encoded a dehydrogenase that reduces pyruvate to o-Iactate, a substrate for the
vanA product; and vanX, which encodes a 0, o-dipeptidase that hydrolyzes o-Ala-

o-Ala produced by the host ligase.

Tn 1546 also includes two accessory

glycopeptide-resistance genes: van Y, encoding a 0, o-carboxypeptidase that
cleaves the C-terminal o-Ala of peptidoglycan precursors, and vanZ, which
encodes a teicoplanin-resistance determinant; two genes, vanR and vanS,
encoding a two-component system that regulates expression of glycopeptide
resistance; and two transposition genes. Two other types of glycopeptide
resistance, VanS and VanC, have also been identified in the enterococci. Like
VanA resistance, these rely on the production of o-Ala-o-Ala ligases. The vanB
gene cluster, which encodes a vancomycin-resistant, teicoplanin-sensitive
phenotype, is encoded on the 64-kb composite transposon Tn 1547.
Significantly, Tn 1547 is bounded on one side by the staphylococcal insertion
sequence IS256 and on the other by IS 16, which is highly similar to IS256?9
Unlike the enterococci, reduced susceptibility to vancomycin and
teicoplanin in the staphylococcal appears not to be due to ligases with altered
substrate specificity, since resistant staphylococci produce peptidoglycan
precursors terminating in o-Ala-o-Ala. High-level vancomycin resistance as seen
in the enterococci has not been observed in clinical staphylococcal strains.
However, the conjunctive co-transfer both in vitro and in vivo of vancomycin
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resistance, along with other resistances, from E. faecalis to S. aureus has been
demonstrated. The S. aureus transconjugants were subsequently resistant to
high levels of vancomycin, although they were unable to transfer resistance to
other S. aureus strains and resistance was lost in the absence of selective
pressure. 80 Thus, it seems likely that the emergence of staphylococcal strains
resistant to high levels of vancomycin is only a matter of time. This scenario
would have great ramifications for the treatment of serious S. aureus infections.
However, it is hoped that with the growing knowledge of the mechanistic basis of
resistance and its evolution at the molecular and genetic level, new strategies
can be devised to reduce the impact of this devastating public health problem.
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Figure 1: Kinetic parameters of the four variants of

~-Iactam

Cephaloridine
Cefazolin
Nitrocefin
Benzylpenicillin
Ampicillin

Kcat
1.95
1.01
23.2
171
308

Type A
Km
10.9
18.4
6.4
51.1
255

~-Iactamase

REH
100
31
2,034
1,869
675

(

of Staphylococcus aureus

Kcat
6.65
4.68
16.5
156
412

Type B
Km
19.4
254
15.7
38.6
160

REH
191
10
587
2,258
1,438

Kcat
5.61
3.94
13.7
210
355

TypeC
Km
11.5
267
20.4
55.9
122

REH
273
9
293
2,098
1,685

Kcat
1.25
1.91
25.6
46
133

Type D
Km
7.9
49.9
5.9
112.6
129

REH
88
21
2,424
228
571

Abbreviations: Kcat molecules of substrate hydrolyzed per second; Km, in Jlm; REH, relative efficiency of hydrolysis (Kcat/Km) relative to cephaloridine set at 100
(Data from Rowland et al)

